Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.5
2.4
Journals
Healthcare
Special Issues
Technological Advances, Precision Medicine and Regulatory Improvements in Drug Safety...
share announcement

Technological Advances, Precision Medicine and Regulatory Improvements in Drug Safety and Pharmacy Support

A special issue of Healthcare (ISSN 2227-9032).

Deadline for manuscript submissions: 1 November 2025 | Viewed by 514

Special Issue Editor

Prof. Dr. Janko Samardžić

E-Mail Website
Guest Editor
Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
Interests: neuropsychopharmacology; neuroscience; GABA; glutamate; pharmacogenetics; pharmacotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Advances in drug safety and pharmacy support have evolved rapidly due to regulatory improvements, technological innovation and a deeper understanding of pharmacology. These advances aim to ensure the safety, efficacy and availability of medicines while reducing the risks associated with drug use. Key developments here revolve around the topics of pharmacovigilance and real-world data, precision medicine, therapeutic drug monitoring (TDM), and artificial intelligence and machine learning in drug safety. Furthermore, regulatory authorities, such as the FDA and EMA, have been enhancing their post-marketing surveillance systems.

The future of drug safety and pharmacy support is bright, with technological advances, tailored pharmacotherapy and regulatory improvements continuing to have a significant impact. From AI-driven safety monitoring to precision medicine, these innovations help ensure that drugs are used safely and effectively, ultimately improving patient outcomes.

This Special Issue aims to bring together experts to share cutting-edge research or reviews on drug safety and pharmacy support. All types of clinical studies that improve patient care and management, including (but not limited to) those on pharmacovigilance, precision medicine, therapeutic drug monitoring (TDM), regulatory improvements and post-marketing surveillance, and artificial intelligence and machine learning in drug safety, are welcome.

We look forward to receiving your contributions.

Prof. Dr. Janko Samardžić
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug safety
  • pharmacovigilance
  • precision medicine
  • therapeutic drug monitoring
  • post-marketing surveillance
  • artificial intelligence
  • machine learning
  • clinical pharmacology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1329 KiB  
Article
Five-Year Trends in SSRI Consumption: A Precision Medicine Approach to Comparative Analysis Between Serbia and European Countries
by Janko Samardžić, Filip Simović, Kristina Sekanić and Milica Branković
Healthcare 2025, 13(10), 1174; https://doi.org/10.3390/healthcare13101174 - 18 May 2025
Viewed by 225
Abstract
Background/Objectives: Mental diseases are one of the leading groups of health disorders worldwide, with depressive and anxiety disorders being the most prevalent. Depressive disorders can be treated with pharmacotherapy, psychotherapy, or a combination of both. In cases where these approaches prove ineffective, [...] Read more.
Background/Objectives: Mental diseases are one of the leading groups of health disorders worldwide, with depressive and anxiety disorders being the most prevalent. Depressive disorders can be treated with pharmacotherapy, psychotherapy, or a combination of both. In cases where these approaches prove ineffective, electroconvulsive therapy may be considered as an alternative. The drugs of choice for treating depressive disorders are selective serotonin reuptake inhibitors (SSRIs). In the Republic of Serbia, commonly prescribed SSRIs include fluoxetine, citalopram, paroxetine, sertraline, and escitalopram. Methods: Data on drug sales for human medicine from the Agency for Medicines and Medical Devices of Serbia (ALIMS) were used for the analysis of consumption in the period 2018–2022. Data on drug consumption in other European countries were obtained from the respective national registers. Results: From 2018 to 2021, sertraline was the best-selling drug in this group, but with a statistically significant decrease (R2 = 0.7948, p = 0.042), while escitalopram showed a statistically significant increase (p = 0.006) and became the best-selling drug in the SSRI group in 2022. Overall, SSRI group consumption fluctuated from 2018 to 2022, with the highest values in 2020. However, these variations were not statistically significant (p = 0.6223). Compared to Serbia, out of 12 European countries, 8 had higher and 4 had lower consumption in 2019 and 2020. A positive correlation was found between antidepressant consumption and GDP per capita. Conclusions: Sertraline was the most commonly prescribed SSRI drug in Serbia from 2018 to 2021. However, in 2022, escitalopram became the most commonly used drug in this group both in Serbia and worldwide, with a consistent increase in consumption. Full article
(This article belongs to the Special Issue Technological Advances, Precision Medicine and Regulatory Improvements in Drug Safety and Pharmacy Support)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop